BioVaxys Technology Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVAXF research report →
About the company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option.
- CEO
- James Christopher Passin
- IPO
- 2018
- Employees
- 3
- HQ
- Etobicoke, BC, CA
Price Chart
- Market Cap
- $4.52M
- P/E
- -0.62
- P/S
- 0.00
- P/B
- -0.56
- EV/EBITDA
- -0.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 121.88%
- ROIC
- 95.65%
- Revenue
- $0 · 0.00%
- Net Income
- $-3,954,781 · 48.55%
- EPS
- $-0.20 · 64.75%
- Op Income
- $-3,122,149
- FCF YoY
- -176.68%
- 52W High
- $0.29
- 52W Low
- $0.02
- 50D MA
- $0.13
- 200D MA
- $0.14
- Beta
- 1.09
- Avg Volume
- 92.11K
Get TickerSpark's AI analysis on BVAXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BVAXF coverage
Recent articles, reports, and earnings notes.
No research on BVAXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BVAXF report →Similar companies
Peers in the same neighborhood.